When myeloma awareness goes mobile

Michael and I lived a traditional American lifestyle: he worked full time in the manufacturing industry while I stayed at home to raise our two young children. Our youngest was just two years old when Michael began experiencing serious back pain. We never imagined that the symptoms would mark the beginning of Michael's lifelong battle against cancer.

In 2000, at the age of 36, Michael was diagnosed with multiple myeloma, a cancer of cells in the bone marrow that affects production of red cells, white cells and stem cells, and can damage bone. Myeloma is also a cancer--as he was told by doctors--for which there was no cause or cure, and which had on average a five-year survival rate.

A five-year survival rate?

When we heard that, our first thoughts were for our children. Mikey was barely walking and Allison was only seven years old. We were devastated, but Michael was not willing to accept the idea that he wouldn't be there to watch them grow up.

Thirteen years later, Michel, the kids and I look back with gratitude that my stubborn husband refused to believe the doctors' prognosis. Allison is now a sophomore in college and just turned 20, and Mikey is already in high school. We are defying the odds 13 years later, and none of us takes a millisecond of life for granted.

One of the ways we show our gratitude is by taking every opportunity to share what we've learned to help others who are struggling with the disease. Educating patients and doctors about myeloma, a disease that is growing in numbers and affecting increasingly younger people, has become our mission--particularly during March, which is Myeloma Awareness Month.

Like most patients at the time of diagnosis, neither Michael nor I had ever heard of myeloma. Fortunately, the International Myeloma Foundation (IMF) was there to help us find expert doctors and learn about the latest treatments and clinical trials of new drugs. The IMF also inspired us to reach out to others in our community who were struggling with myeloma and establish the first myeloma support group in our home state of Connecticut. Today we enjoy hosting monthly meetings with our fellow myeloma patients and caregivers--learning, sharing and celebrating our personal milestones as a group.

There have been some very scary moments since myeloma entered our lives. After an operation left Michael paralyzed for two months, he needed to re-learn to stand, walk and perform routine things again as simple as putting on his socks and shoes each morning, and was forced to stop working. I cannot tell you how much I admire his strength. He never gave up, and when the time came, he was able to recover enough to help coach Mikey's baseball team.

Though it was Michael who had to suffer through the radiation treatment to shrink a large plasma cell tumor that had destroyed two-thirds of his sacrum, a successful stem cell transplant, and an operation that resulted in irreparable nerve damage in both his legs--we faced the successes and setbacks together as a family.

Then--as is frequently the case with myeloma patients--Michael's disease returned. This time, after much debate, his doctors at New York-Presbyterian Hospital/Weill Cornell Medical Center settled on a course of treatment (a combination of Revlimid and dexamethasone) that worked.

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Special Feature
Share Your Art
Related Articles
BRCA Mutations May Cause Drug Resistance in Breast and Ovarian Cancer
There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.
Sarah Sciortino on Fertility and Sexuality in Younger Patients with Ovarian Cancer
Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.
Caring With Confidence: Study Examines Caregiver Mastery and Patient Survival in GBM
A recent study found that the level of family caregiver mastery may have an effect on the survival of patients with glioblastoma.
Related Videos
Examining Quality of Life Issues for Patients With MPNs
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Elliott Winton on the Changing Landscape of MPN Treatment
Elliott Winton, M.D., researcher, physician and 2016 MPN Hero, discusses some of the drastic changes that happened over the past decade or so in the world of MPNs. 
Siddhartha Mukherjee on Increasing MPN Awareness
Siddhartha Mukherjee, M.D., Ph.D, an oncologist, researcher and Pulitzer Prize-winning science writer, discusses the increasing awareness about myeloproliferative neoplasms (MPNs).
//For side ad protocol